Implied return -15% to our target. Bear to bull $168.75 to $428.07, from our initiation of Nov 20, 2026. We expect a total return worse than −10% over the next 12 months: a fall of more than 10%, after dividends.
Primary P/E: 11.5x (restated peer median) on FY27E adjusted EPS of $23.52, less $4.08 of expected RADV cost, gives a $266.36 base value. Bear, base and bull values of $168.75, $266.36 and $428.07 are weighted 25/50/25% to $282.39 and rolled forward 12 months at 5.46% (8.18% cost of equity less the 2.72% dividend yield) to the $297.81 target. A 10-year FCFE DCF cross-check gives $537.
Bear case
$168.75
-52% from $349.91
FY27E adjusted EPS $17.18 at 10.5x lowest-peer P/E
$11.66 full RADV (100% upheld)
UHC margin 3.0%
Optum Health margin 2.0%
Base case
$266.36
-24% from $349.91
FY27E adjusted EPS $23.52 at 11.5x peer-median P/E